健择联合顺铂治疗晚期非小细胞肺癌临床观察  

Clinical observation of effect of Gemzar combined with cisplatinin treatment of advanced nonsmall-cell lung cancer

作　　者：操乐杰[1] 李润生[1] 雷祖宝[1] 许迪威[1] 

机构地区：[1]安徽医科大学附属省立医院呼吸科,230001

出　　处：《临床肺科杂志》2006年第3期282-283,共2页Journal of Clinical Pulmonary Medicine

基　　金：安徽省科技厅重点科研基金资助(编号:0102304;05023086)

摘　　要：目的了解健择联合顺铂方案治疗晚期非小细胞肺癌有效性和安全性。方法采用回顾性分析法总结近1年采用健择联合顺铂方案初治的晚期非小细胞肺癌资料,按照WHO的标准评价疗效和不良反应。结果31例晚期非小细胞肺癌采用健择联合顺铂方案治疗,近期有效率达45.2%,而不良反应发生率小于15%,治疗后患者体重增加。结论健择联合顺铂方案治疗晚期非小细胞肺癌疗效较高、不良反应小、安全性高,值得推广应用。Objective To observe curative effect and adverse reactions of Gemzar （Gemcitabine） combined with cisplatin in the treatment of advanced non-smallcell lung cancer （NSCLC） patients. Methods A retrospective study was conducted on the advanced NSCLC patients who were given Gemzar combined with cisplatin in the past 24 months. The data were measured and evaluated based on WHO standard, Results 31 cases were assigned to the treatment group. Of those, 45.2%showed short-term treatment effect with lower adverse reactions （below 15%）, There body weight has increased afte the treatment Conclusion Gemzar combined with cisplatin is effective with lower adverse reaction. It is safe and worthy of a wide use for NSCLC patients.

关 键 词：健择 吉西他滨 化疗 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤] R521[医药卫生—临床医学]